Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haleon’s separation from GSK created a consumer-health giant with dozens of power brands—and a web of disclosures that can overwhelm even seasoned analysts. Sales are broken out across oral care, pain relief, vitamins and more, while its first standalone Form 20-F runs hundreds of IFRS-heavy pages. If you have ever asked, "Where do I find Haleon insider trading Form 4 transactions" or "How do I decode Haleon’s quarterly earnings report 10-Q filing?", you know the challenge.
Stock Titan solves it. Our AI reads every new filing the moment it hits EDGAR, then delivers plain-English summaries, red-flags and searchable key terms. Whether you need Haleon Form 4 insider transactions in real-time, a side-by-side view of segment revenue from the latest 6-K, or want Haleon SEC filings explained simply, the platform highlights what matters: advertising spend trends, litigation provisions, post-spin debt covenants and more. Long-tail queries such as "Haleon executive stock transactions Form 4", "understanding Haleon SEC documents with AI", or "Haleon earnings report filing analysis" resolve to the exact section—no scrolling required.
All filing types are here, updated continuously: the Haleon annual report 10-K simplified (20-F), Haleon proxy statement executive compensation, and every Haleon 8-K material events explained. Use our tools to:
- Track insider buying and selling before marketing launches
- Compare vitamin and mineral supplement growth quarter-over-quarter
- Spot supply-chain disclosures in material event filings
Haleon has completed the acquisition of the remaining 12% equity stake in Tianjin TSKF Pharmaceutical Co. Ltd (TSKF), its Chinese OTC joint venture, for RMB 1,623 million (approximately £0.2 billion). This transaction makes TSKF a wholly-owned subsidiary of Haleon.
Key highlights of the acquisition:
- TSKF represented approximately 40% of Haleon's China revenues in 2024
- The joint venture manufactures and distributes leading brands including Fenbid, Voltaren, and Bactroban
- China is identified as a key strategic market with favorable structural drivers
- The acquisition aims to enhance strategic and operational flexibility in one of the fastest-growing OTC markets globally
The transaction aligns with Haleon's capital allocation strategy, focusing on driving attractive shareholder returns while maintaining a strong investment-grade balance sheet. This strategic move strengthens Haleon's position as a global leader in consumer health, with a portfolio spanning Oral Health, VMS, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Haleon has reported a significant share buyback transaction as part of its program announced on March 28, 2025. On June 24, 2025, the company purchased 1,009,135 ordinary shares for cancellation, with prices ranging from 383.70p to 388.40p per share, at a volume-weighted average price of 385.76p.
Following this transaction, Haleon's registered share capital consists of 8,989,539,664 ordinary shares, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,985,459,459, a figure shareholders should reference for FCA disclosure requirements.
Key Information:
- Share buyback program continues as announced on March 28, 2025
- Transaction date: June 24, 2025
- Highest price paid: 388.40p per share
- Lowest price paid: 383.70p per share
- Volume weighted average price: 385.76p per share
Haleon has announced a significant share buyback transaction as part of its program launched on March 28, 2025. On June 23, 2025, the company purchased 1,008,610 ordinary shares for cancellation at prices ranging from 381.50p to 387.90p per share, with a volume-weighted average price of 385.10p.
Following the transaction, Haleon's registered share capital consists of 8,990,548,799 ordinary shares, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,986,468,594, a figure relevant for shareholder disclosure requirements under FCA regulations.
Haleon, a global consumer health leader listed on LSE/NYSE (HLN), maintains a portfolio across six major categories including Oral Health, VMS, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Key brands include Advil, Centrum, Sensodyne, and Voltaren.
Haleon has announced a significant share buyback transaction as part of its program announced on March 28, 2025. On June 20, 2025, the company purchased 1,016,186 ordinary shares for cancellation at prices ranging from 382.70p to 388.00p per share, with a volume-weighted average price of 385.10p.
Following the settlement, Haleon's registered share capital consists of 8,991,557,409 ordinary shares of £0.01 each, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,987,477,204.
Haleon, a global consumer health leader listed on LSE/NYSE, maintains a portfolio across six major categories:
- Oral Health
- Vitamins, Minerals and Supplements (VMS)
- Pain Relief
- Respiratory Health
- Digestive Health
- Therapeutic Skin Health
The company's brand portfolio includes notable names such as Advil, Centrum, Sensodyne, and Voltaren.
Haleon has reported a significant share buyback transaction as part of its program announced on March 28, 2025. On June 19, 2025, the company purchased 1,011,111 ordinary shares for cancellation at prices ranging from 382.80p to 384.90p per share, with a volume-weighted average price of 383.82p.
Following this transaction, Haleon's registered share capital consists of 8,992,573,595 ordinary shares, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,988,493,390, a figure relevant for shareholders' disclosure requirements under FCA rules.
Haleon, a global consumer health leader listed on LSE/NYSE (HLN), maintains a portfolio across six major categories:
- Oral Health
- Vitamins, Minerals and Supplements
- Pain Relief
- Respiratory Health
- Digestive Health
- Therapeutic Skin Health
On 19 June 2025, Haleon plc (LSE/NYSE: HLN) filed a Form 6-K reporting activity under the share buyback programme launched on 28 March 2025. On 18 June 2025 the company repurchased 1,009,204 ordinary shares of £0.01 each for cancellation.
Key transaction metrics
- Shares purchased: 1,009,204
- Price range: 382.90 p – 386.70 p
- Volume-weighted average price: 384.87 p
- Purpose: Cancellation under authorised Buyback Programme
Post-settlement, registered share capital totals 8,993,584,706 ordinary shares, of which 4,080,205 are held in treasury. The resulting number of ordinary shares with voting rights is 8,989,504,501. Investors should apply this updated figure when assessing FCA disclosure thresholds.
A trade-by-trade schedule, published to comply with Article 5 of the UK Market Abuse Regulation, is available via the London Stock Exchange link provided. The filing reiterates that the announcement is not an offer to sell or solicit securities and supplies contact details for investor and media enquiries.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
What is Haleon and what are its core business areas?
How does Haleon generate its revenue?
How is Haleon positioned in the global consumer health market?
What differentiates Haleon from its competitors?
What role does innovation play at Haleon?
How does Haleon address regional consumer preferences?
Can you elaborate on Haleon’s product categories?
What should investors know about Haleon?
